HC Wainwright reissued their buy rating on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a report published on Wednesday morning, AnalystRatings.com reports. They currently have a $15.50 price objective on the biotechnology company’s stock.
Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Pluristem Therapeutics from a hold rating to a buy rating and set a $4.25 price objective on the stock in a research note on Thursday, October 17th. LADENBURG THALM/SH SH started coverage on shares of Pluristem Therapeutics in a research note on Monday, July 22nd. They issued a buy rating on the stock. Finally, ValuEngine cut shares of Pluristem Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Pluristem Therapeutics currently has a consensus rating of Buy and a consensus target price of $9.25.
Shares of NASDAQ PSTI traded up $0.03 during midday trading on Wednesday, hitting $3.23. The company’s stock had a trading volume of 23,200 shares, compared to its average volume of 72,100. Pluristem Therapeutics has a 1-year low of $3.17 and a 1-year high of $11.90. The firm’s fifty day moving average price is $3.55 and its 200-day moving average price is $2.47. The company has a current ratio of 2.74, a quick ratio of 3.23 and a debt-to-equity ratio of 0.07.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Featured Story: Swap
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.